surmount-1 tirzepatide 15 mg weight loss percent reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism SURMOUNT 1 // Three-Year Obesty
Description
The metabolic improvements they produce may ultimately matter more for long-term health than the number on the scale
By interacting with the melanocortin-4 receptor, tirzepatide can promote energy expenditure
these are reported here for research context only
Fatigue sets in
We need to ensure we're reaching out to the breadth of patients who could potentially benefit from this
